

Expected submission *timelines*

| 2023 → | | 2024 → | | 2025 and beyond → | |
|--|--|---|---|--|--|
| Dupixent^{®A} Chronic Inducible Cold Urticaria | Kevzara^{®A} Polyarticular juvenile idiopathic arthritis | Dupixent^{®A} COPD | Nexvazyme[®] Pompe Disease - Infantile Onset | Dupixent^{®A} CPUO | Sarclisa[®] SubQ 3L RR MM (IRAKLIA) |
| Dupixent^{®A} Allergic Fungal Rhinosinusitis | Sarclisa[®] 1L Newly Diag. MM T1 (IMROZ) | venglustat GM2 gangliosidosis | rilzabrutinib ITP | Dupixent^{®A} Bullous pemphigoid | tolebrutinib PPMS |
| Sarclisa[®] 1L Newly Diag. MM Te (GMMG) | fitusiran Hemophilia A/B | tusamitamab ravtansine 2/3L NSCLC | MenQuadfi[®] 6W+ | Dupixent^{®A} Chronic Sinusitis without Nasal Polyps | tolebrutinib SPMS |
| tolebrutinib RMS | | | | Kevzara^{®A} Systemic Juvenile Arthritis | venglustat Gaucher Type 3 |
| | | | | amlitelimab Atopic Dermatitis | venglustat Fabry Disease |
| | | | | itepekimab^A COPD | fitusiran Hemophilia A/B ped |
| | | | | Sarclisa[®] Smoldering MM | VRVg Purified vero rabies vaccine |

| | |
|---|----------------------|
| ■ | Immuno-inflammation |
| ■ | Oncology |
| ■ | Neurology |
| ■ | Rare Diseases |
| ■ | Rare Blood Disorders |
| ■ | Vaccines |

As of December 31, 2022. For collaborations see slide 54. For abbreviations see slide 55.
Excluding Phase 1 and 2 (without Proof of Commercial Concept); Projects within a specified year are not arranged by submission timing.